Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2023 09:00 ET | Source: Aerami Therapeutics Inc

Aerami Therapeutics to Present at Biotech Showcase™ 2023 during the 41st Annual J.P. Morgan Healthcare Conference Week

DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary...
December 21, 2022 08:01 ET | Source: Aerami Therapeutics Inc

Aerami Therapeutics Announces Completion of Dosing in Phase 1 Trial of AER-901 (inhaled imatinib), a Critical Milestone Toward the Planned Initiation of a Phase 2 Trial in Pulmonary Arterial Hypertension (PAH) During the First Half of 2023

AER-901 (inhaled imatinib), a potential reverse-remodeling therapy, is being developed to address unmet need for PAH treatments that target pulmonary vascular remodeling while supporting ease-of-use...
December 21, 2022 08:00 ET | Source: Aerami Therapeutics Inc

Aerami Therapeutics Appoints Lisa Yañez as Chief Executive Officer

Lisa Yañez Incoming Chief Executive OfficerAerami Therapeutics DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Aerami Therapeutics Holdings, Inc (“Aerami”), a clinical-stage biopharmaceutical...
June 16, 2022 09:00 ET | Source: Aerami Therapeutics Inc

Aerami Therapeutics Appoints Lisa Yañez as Chief Operating Officer

DURHAM, N.C., June 16, 2022 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (the “Company”), a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory and other...
August 25, 2021 09:00 ET | Source: Aerami Therapeutics Inc

Aerami Therapeutics Announces Orphan Drug Designation for Imatinib for the Treatment of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) affects almost 68,000 patients worldwide, with treatment limited to vasodilators, none of which are disease-modifyingDosing of patients in Phase 1 trial is...
February 09, 2021 09:00 ET | Source: Aerami Therapeutics Inc

Aerami Therapeutics Signs License Agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. for Aerami’s PAH (pulmonary arterial hypertension) Drug Device Combination in China

DURHAM, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (“Aerami” or the “Company”) a clinical stage biopharmaceutical company developing inhaled therapies to treat severe...